Invex Therapeutics Ltd. (IXC) AI Stock Analysis

• Market Cap: AU$7.52M
• Dividend Yield: N/A
• Average Volume (3M): 49.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: N/A
• EPS Growth: 71.10%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 75,153,850
• 10 Day Avg. Volume: 15,093
• 30 Day Avg. Volume: 49,574
• PEG Ratio: 0.20
• Price to Book (P/B): 1.28
• Price to Sales (P/S): 29.41
• P/FCF Ratio: -10.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: AU$0.10 ▼(-17.50% Downside)
• Action: Reiterated Date: 01/21/26
• Date: Action: Reiterated 01/21/26

The score is primarily held back by weak financial performance (volatile and sharply lower revenue, ongoing losses, and persistent cash burn), with some support from a debt-free balance sheet and improving loss/cash outflow trends. Technicals are neutral overall, while valuation remains unattractive due to negative earnings and no dividend yield data.

Positive Factors

Debt-free balance sheet

Zero debt provides a durable reduction in financial risk for a clinical-stage biotech. With no interest burden the company can prioritize R&D and clinical milestones, extending flexibility to raise capital on more favourable terms over the next 2–6 months if needed.

Improving cash outflow trend

Sequential improvement in cash outflow signals better cost control and slower runway depletion. If sustained, this trend increases the likelihood management can reach clinical inflection points with less frequent capital raises, improving strategic optionality over coming quarters.

Focused clinical-stage portfolio with IIH lead program

A clear, focused pipeline targeting IIH gives the company concentrated R&D efforts and a specific regulatory pathway. Specialization can attract targeted partnerships or grants and allows management to allocate resources toward one high-impact program over the medium term.

Negative Factors

Steep revenue decline and volatility

An ~81% revenue collapse and high volatility indicate weak commercial traction and unreliable recurring income. For a clinical-stage biotech reliant on funding, this persistent revenue instability raises execution risk and increases dependence on external financing over months ahead.

Persistent negative operating and free cash flow

Consistent negative operating and free cash flow demonstrates the business cannot self-fund operations. Even with recent improvement, ongoing burn requires external capital or partnerships, which could dilute shareholders or constrain strategic choices over the medium term.

Ongoing operating losses and negative returns on equity

Sustained operating losses and negative ROE signify value dilution and limited near-term profitability. Without a clear path to sustained positive margins, the company faces pressure to either materially cut spending or pursue dilutive funding, both of which impact long-term shareholder value.

Invex Therapeutics Ltd. Business Overview & Revenue Model

Company Description

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.

How the Company Makes Money

null

Invex Therapeutics Ltd. Financial Statement Overview

Summary

Financials reflect an early-stage biotech profile: steeply volatile and shrinking revenue (2025 down ~81% YoY), ongoing operating/net losses, and consistently negative operating/free cash flow. Offsetting this, losses and cash outflow improved versus 2024 and the company is debt-free with a meaningful (though declining) equity base.

Income Statement

Revenue is small and highly volatile, with a steep decline in the latest year (2025 revenue down ~81% vs. 2024). Profitability remains weak with persistent operating losses and net losses across all periods shown, although losses have narrowed materially versus 2022–2023. Gross profit is positive when revenue exists, but overall margins remain deeply negative, indicating the business is still far from self-funding.

Balance Sheet

The balance sheet is conservatively positioned with zero debt and a meaningful equity base, which reduces financial risk. However, equity has trended down significantly from 2022–2023 levels, consistent with ongoing losses and cash burn. Returns on equity are negative each year, reflecting continued value dilution risk if losses persist.

Cash Flow

Operating cash flow and free cash flow are negative in every year shown, signaling consistent cash burn. The latest year shows a sizable improvement in cash outflow versus 2024, but cash generation is still not sustainable without external funding. Cash flow performance remains closely tied to losses, and the business has not demonstrated durable positive operating cash generation.

Breakdown	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	229.08K	1.21M	459.08K	182.25K	0.00
Gross Profit	229.08K	1.21M	459.08K	182.25K	0.00
EBITDA	0.00	-720.00K	-8.21M	-4.14M	-2.28M
Net Income	-476.87K	-1.64M	-7.75M	-3.95M	-2.28M
Balance Sheet
Total Assets	5.47M	6.12M	22.80M	29.49M	32.74M
Cash, Cash Equivalents and Short-Term Investments	5.38M	6.03M	22.47M	29.34M	32.72M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	220.59K	431.63K	1.57M	1.00M	658.61K
Stockholders Equity	5.25M	5.69M	21.23M	28.48M	32.08M
Cash Flow
Free Cash Flow	-652.57K	-2.44M	-6.87M	-3.38M	-1.68M
Operating Cash Flow	-652.57K	-2.44M	-6.87M	-3.38M	-1.68M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	0.00	-14.00M	0.00	0.00	8.09M

Invex Therapeutics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IXC, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.12, and above the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 19.99 is Positive, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IXC.

Invex Therapeutics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IXC	48 Neutral	AU$7.52M	-3.15	-17.07%	―	―	71.10%
CHM	45 Neutral	AU$8.84M	-0.15	2844.96%	―	―	46.28%
ATH	41 Neutral	AU$76.13M	-2.12	-30.19%	―	―	63.46%
RCE	41 Neutral	AU$154.71M	-2.84	279.21%	―	―	0.66%
ADO	40 Underperform	AU$32.70M	-10.60	-142.30%	―	110.44%	35.90%
1AD	37 Underperform	AU$10.20M	-0.48	1068.18%	―	―	31.87%

Invex Therapeutics Ltd. Corporate Events

Invex Reports Promising Exenatide Data in Alzheimer’s ADBrain™ Model

Invex Therapeutics reported new data from its research collaboration with Tessara Therapeutics, showing that exenatide demonstrated multiple potentially beneficial effects in Tessara’s ADBrain™ model of Alzheimer’s disease. In the latest analysis, exenatide reduced neurofilament light chain levels by about 40%, lowered pro‑inflammatory cytokines IL-6 and IL-8, and improved measures of neural network complexity such as branching and branch length, while not significantly affecting phosphorylated tau or insulin‑dependent glucose uptake under the tested conditions; the company views these findings as supportive of exenatide’s potential therapeutic benefit early in Alzheimer’s disease and intends to investigate the observed effects on amyloid‑beta burden further.

The most recent analyst rating on (AU:IXC) stock is a Sell with a A$0.11 price target. To see the full list of analyst forecasts on Invex Therapeutics Ltd. stock, see the AU:IXC Stock Forecast page.

Invex Therapeutics Sets Date and Details for 2025 Annual General Meeting

Invex Therapeutics has announced that its 2025 Annual General Meeting will be held in person at Pathways Corporate in Perth on 17 February 2026 at 3:00pm AWST, with the Notice of Meeting and Explanatory Memorandum made available online via the company’s website and the ASX platform. Shareholders are encouraged to lodge their votes by proxy through Automic’s online portal using their securityholder details, and can obtain meeting materials or raise queries electronically, underscoring the company’s continued use of digital channels for governance communications and shareholder engagement.

The most recent analyst rating on (AU:IXC) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Invex Therapeutics Ltd. stock, see the AU:IXC Stock Forecast page.